Business
ImmunityBio Announces Positive Phase 2 Results Showing That Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer
Clinical benefit observed in majority of NSCLC patients who progressed on checkpoint inhibitor Anktiva™ (also called N-803) restored or enhanced activity of
About this update from Immunitybio, Inc.
[{"type":"text","content":"\n\nClinical benefit observed in majority of NSCLC patients who progressed on checkpoint inhibitor\n\n\nAnktiva™ (also called N-803) restored or enhanced activity of checkpoint therapy even in those who progressed on the same checkpoint \n\n\nActivity observed regardless of PD-L1 status and prior response to checkpoint inhibitor therapy\n\n\nAnktiva combination therapy with checkpoint inhibitors is well tolerated with low incidence of adverse events and could potentially serve as the backbone to all checkpoint inhibitor therapies\n\n\n CULVER CITY, Calif.--(BUSINESS WIRE)--\nImmunityBio, Inc., a privately held immunotherapy company, today announced the presentation of encouraging data in non-small cell lung cancer (NSCLC) from the company’s ongoing Phase 2b study, QUILT-3.055 (ClinicalTrials.gov: NCT03228667) at the International Association for the Study of Lung Cancer (IASCL)’s 2020 World Conference on Lung Cancer, Singapore, being held virtually January 28 – 31, 2021.\n\nThe presentation, titled “QUILT 3.055: a phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors in NSCLC,” highlighted safety and efficacy data from NSCLC patients in Cohort 1 of the study (N=78), which is evaluating patients with initial response on single-agent checkpoint inhibitor therapy who subsequently progressed on or after that therapy in multiple tumor types. The study is designed to evaluate combination immunotherapy regimens that include ImmunityBio’s lead cytokine infusion protein, a novel interleukin-15 (IL-15) superagonist complex (Anktiva™, also called N-803) in patients who have previously received treatment with PD-1/PD-L1 immune checkpoint inhibitors. Anktiva has been engineered to exhibit a longer half-life and more potent trans-presentation relative to endogenous IL-15 to promote natural killer (NK) cell and T cell expansion to control cancer.\n\nKey presentation results include:\n\n\nClinical benefit was demonstrated in a majority of the NSCLC patients, as measured by reduction of target lesion size and cessation of progression in the target lesion over time (with follow-up of up to 13 months).\n\n\nClinical benefit was observed in patients with immediate prior progression on checkpoint inhibitors when Anktiva was combined with the checkpoint inhibitor, regardless of PD-L1 status or use of chemot...